Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | PREP | P48147 | 5/20 | 0.58 |
| ▸ | KLK7 | P49862 | 1/20 | 0.55 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974458 | 0.97 | HSD17B10 (0.55) | HSD17B10PREPKLK7UCHL1NPC1 | |
| SCHEMBL6201175 | 0.94 | PREP (0.58) | HSD17B10PREPKLK7UCHL1NPSR1 | |
| SCHEMBL6201170 | 0.94 | PREP (0.58) | HSD17B10PREPKLK7UCHL1NPSR1 | |
| SCHEMBL2960273 | 0.93 | PREP (0.57) | HSD17B10PREPKLK7NPSR1 | |
| SCHEMBL9354156 | 0.88 | PREP (0.64) | PREPMEN1KMT2ANPC1RAB9A | |
| SCHEMBL11262912 | 0.88 | PREP (0.69) | HSD17B10PREPKLK7KMT2ANPSR1 | |
| SCHEMBL11262909 | 0.88 | PREP (0.69) | HSD17B10PREPKLK7KMT2ANPSR1 | |
| SCHEMBL3396768 | 0.86 | HSD17B10 (0.60) | HSD17B10KLK7UCHL1MEN1KMT2A | |
| SCHEMBL7307432 | 0.86 | KLK7 (0.61) | HSD17B10PREPKLK7MEN1KMT2A | |
| SCHEMBL9609458 | 0.86 | KLK7 (0.61) | HSD17B10PREPKLK7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | HSD17B10 2070/4885PREP 4080/4885KLK7 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.